Morphogen-IX, a Cambridge, UK-based biotech company, raised £1.5m in seed funding.
The round was led by Index Ventures, with participation from Cambridge Innovation Capital and Cambridge Enterprise Seed Funds.
The company intends to use the funds to develop a new treatment for pulmonary arterial hypertension (PAH) that directly targets the major pathway implicated in human genetic studies.
Morphogen-IX is advancing a new treatment for pulmonary arterial hypertension (PAH) – based on 15 years of work by Professor Nick Morrell and his team at the University of Cambridge’s Department of Medicine at Addenbrooke’s Hospital – which has the potential to provide a disease-modifying approach to this condition.
The company has worked closely with British Heart Foundation (BHF) Centre of Research Excellence at the University of Cambridge and Cambridge Enterprise, the commercialization arm of the University of Cambridge, to license the intellectual property arising from Professor Morrell’s research.